OncoCyte (NASDAQ:OCX) Lowered to “Neutral” at Chardan Capital

OncoCyte (NASDAQ:OCX) was downgraded by Chardan Capital from a “buy” rating to a “neutral” rating in a report released on Tuesday, Zacks.com reports.

Shares of OCX stock opened at $3.23 on Tuesday. The stock has a 50-day moving average price of $2.77 and a 200 day moving average price of $2.49. OncoCyte has a 12 month low of $1.50 and a 12 month high of $3.51.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.02 million during the quarter.

OncoCyte Company Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Featured Story: How is the S&P 500 index different from the DJIA?

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.